Differences in the prediction of therapeutic response with the two scoring systems emerged from trials; indeed, the inclusion of immune cells in the CPS leads to an overall average PD-L1 positivity of HNSCC of 85%, while it is around 50–60% when assessed with TPS [12,14]. Here, CD274 is linked to head and neck squamous cell carcinoma.